Ori Biotech Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
73
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$101M
- Investors
-
13
Ori Biotech General Information
Description
Developer of cell and gene therapy (CGT) manufacturing technology intended for flexible process discovery, translation, and scalable commercialization of cell and gene therapies. The company's manufacturing platform fully automates cell and gene therapy (CGT) manufacturing to increase throughput, improve quality, and decrease costs by combining proprietary hardware, software, data, and analytics, enabling therapeutics developers to develop and bring products to market at a commercial scale and patients to access a new generation of personalized and life-saving treatments.
Contact Information
Website
www.oribiotech.comCorporate Office
- 35 Beaufort Court Admirals Way
- South Quay Waterside
- London E14 9XL
- England, United Kingdom
Corporate Office
- 35 Beaufort Court Admirals Way
- South Quay Waterside
- London E14 9XL
- England, United Kingdom
Ori Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 07-Jan-2022 | $101M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series A) | 24-Aug-2020 | Completed | Generating Revenue | |||
| 4. Grant | 01-May-2020 | Completed | Generating Revenue | |||
| 3. Seed Round | 22-Aug-2019 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 04-May-2018 | $270K | $456K | Completed | Generating Revenue | |
| 1. Angel (individual) | 29-Nov-2016 | $187K | $187K | Completed | Generating Revenue |
Ori Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Ordinary | ||||||||
| Series A | ||||||||
| Ordinary | ||||||||
| Seed Preferred | ||||||||
| Seed Ordinary | ||||||||
| Seed Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 134,584 | $0.000134 | $0.6 | $0.6 | 1x | $0.6 | 0.42% | |
| Ordinary | 60,900 | $0.000134 | $0.6 | $0.6 | 1x | $0.6 | 0.19% |
Ori Biotech Comparisons
Industry
Financing
Details
Ori Biotech Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Multiply Labs | Venture Capital-Backed | San Francisco, CA | ||||
| TrakCel | Venture Capital-Backed | Cardiff, United Kingdom | ||||
| Cellares | Venture Capital-Backed | South San Francisco, CA | ||||
| Precision BioSciences | Formerly VC-backed | Durham, NC | ||||
| Biolife Solutions | Corporation | Bothell, WA |
Ori Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ori Biotech Patents
Ori Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202408688-D0 | A connector | Pending | 17-Jun-2024 | ||
| GB-202407574-D0 | An interface for coupling to a cell processing container | Pending | 29-May-2024 | ||
| GB-202312380-D0 | Bioreactor system | Pending | 14-Aug-2023 | ||
| GB-202301148-D0 | A method of transduction | Pending | 26-Jan-2023 | ||
| GB-2626570-A | A method of transduction | Pending | 26-Jan-2023 | C12N5/0636 |
Ori Biotech Executive Team (11)
| Name | Title | Board Seat |
|---|---|---|
| Jason Foster | Chief Executive Officer & Board Member | |
| Gillian Bonthron | Chief Financial Officer | |
| John Machulski | Chief Operating Officer | |
| Stuart Milne | Chief Technology Officer | |
| Farlan Veraitch Ph.D | Co-Founder, Chief Scientific Officer & Board Member |
Ori Biotech Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Wieschhaus Ph.D | Northpond Ventures | Board Member | |
| Andrea Jackson | Self | Board Member | |
| Annalisa Jenkins MD | Self | Board Member | |
| Barry Clare | Self | Chairman | |
| Christopher Mason MD | Self | Co-Founder & Board Member |
Ori Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ori Biotech Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andrea Jackson | Angel (individual) | Minority | ||
| Chimera Capital | Asset Manager | Minority | ||
| Jonathan Hayashi | Angel (individual) | Minority | ||
| Novalis LifeSciences | Venture Capital | Minority | ||
| Paul Meister | Angel (individual) | Minority |
Ori Biotech FAQs
-
When was Ori Biotech founded?
Ori Biotech was founded in 2015.
-
Who is the founder of Ori Biotech?
Farlan Veraitch Ph.D and Christopher Mason MD are the founders of Ori Biotech.
-
Who is the CEO of Ori Biotech?
Jason Foster is the CEO of Ori Biotech.
-
Where is Ori Biotech headquartered?
Ori Biotech is headquartered in London, United Kingdom.
-
What is the size of Ori Biotech?
Ori Biotech has 73 total employees.
-
What industry is Ori Biotech in?
Ori Biotech’s primary industry is Other Devices and Supplies.
-
Is Ori Biotech a private or public company?
Ori Biotech is a Private company.
-
What is the current valuation of Ori Biotech?
The current valuation of Ori Biotech is .
-
What is Ori Biotech’s current revenue?
The current revenue for Ori Biotech is .
-
How much funding has Ori Biotech raised over time?
Ori Biotech has raised $140M.
-
Who are Ori Biotech’s investors?
Andrea Jackson, Chimera Capital, Jonathan Hayashi, Novalis LifeSciences, and Paul Meister are 5 of 13 investors who have invested in Ori Biotech.
-
Who are Ori Biotech’s competitors?
Multiply Labs, TrakCel, Cellares, Precision BioSciences, and Biolife Solutions are some of the 10 competitors of Ori Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
